Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma

BACKGROUND: Recent studies have shown that immune checkpoint inhibitors (ICIs) targeting programmed cell death-ligand 1 (PD-L1) have potential benefits in patients with non-small cell lung cancer (NSCLC) subgroups, while the clinicopathological characteristics associated with PD-L1 expression have n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hengxing, Zou, Xuexue, Wang, Jing, Zhou, Jiejun, Fan, Meng, Chen, Mingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636434/
https://www.ncbi.nlm.nih.gov/pubmed/37969280
http://dx.doi.org/10.21037/jtd-23-523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636434/
https://www.ncbi.nlm.nih.gov/pubmed/37969280
http://dx.doi.org/10.21037/jtd-23-523

Ejemplares similares